摘要
目的探究表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)联合甲磺酸阿帕替尼治疗晚期非小细胞肺癌(NSCLC)的效果及安全性。方法选择中国人民解放军联勤保障部队第九九○医院信阳院区2018年9月至2020年7月收治的86例晚期NSCLC患者作为研究对象。按照治疗方案分为观察组和对照组,对照组42例接受EGFR-TKIs治疗,观察组44例接受EGFR-TKIs联合甲磺酸阿帕替尼治疗。比较两组疾病控制率、血清肿瘤标志物水平及不良反应发生情况。结果观察组疾病控制率(100%)高于对照组(90.48%),差异有统计学意义(P<0.05)。治疗前,两组糖类抗原125(CA125)、癌胚抗原(CEA)、角蛋白19片段(CYFRA21-1)水平比较,差异无统计学意义(P>0.05);治疗后,两组CYFRA21-1、CEA、CA125水平降低,且观察组水平低于对照组,差异有统计学意义(P<0.05)。治疗期间两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论EGFR-TKIs联合甲磺酸阿帕替尼治疗晚期NSCLC患者,可有效提高疾病控制率,降低血清肿瘤标志物水平,安全性可。
Objective To explore the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKIs)combined with apatinib mesylate in the treatment of advanced non-small cell lung cancer(NSCLC)effect and safety.Methods A total of 86 patients with advanced NSCLC admitted to the Xinyang District of the 990th Hospital of the Chinese People’s Liberation Army Joint Service Support Force from September 2018 to July 2020 was selected as the research object.According to the treatment plan,they were divided into observation group and control group.There were 42 cases in the control group received EGFR-TKIs treatment,and 44 cases in the observation group received EGFR-TKIs combined with apatinib mesylate.The clinical efficacy and serum tumor marker levels of the two groups were compared,and the adverse reactions of the two groups of patients after the treatment were recorded.Results The disease control rate of the observation group(100%)was higher than that of the control group(90.48%)(P<0.05).There was no difference before treatment in the levels of CA125,CEA and CYFRA21-1 between the two groups(P>0.05).After treatment,the levels of CA125,CEA and CYFRA21-1 in the two groups were all low,and the observation group was lower than the control group(P<0.05).There was no difference in the incidence of adverse reactions(P>0.05).Conclusion EGFR-TKIs combined with apatinib mesylate in the treatment of patients with advanced NSCLC can effectively improve the disease control rate,reduce the levels of various serum tumor markers,and do not increase the incidence of adverse reactions.
作者
熊安对
潘晓青
XIONG Andui;PAN Xiaoqing(Department of Respiratory Oncology,Xinyang District of the 990th Hospital of the Chinese People’sLiberation Army Joint Service Support Force,Xinyang 464000,China)
出处
《河南医学研究》
CAS
2021年第27期5115-5118,共4页
Henan Medical Research
